Rating Change
HC Wainwright & Co. reiterated its Buy rating on Eton Pharmaceuticals, Inc. (NASDAQ:ETON) on October 14, 2026.
HC Wainwright & Co. reiterated its Buy rating on Eton Pharmaceuticals, Inc.

At publication ·
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) · reiterate
At a glance
HC Wainwright & Co. reiterated its Buy rating on Eton Pharmaceuticals, Inc. (NASDAQ:ETON) on October 14, 2026.
Eton Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $52.88 with a market capitalization of $453.5M.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eton Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 14, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 14, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 14, 2026 | B. Riley Securities | Buy | N/A |
| Aug 14, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 11, 2026 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ETON Stock Page
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Eton Pharmaceuticals, Inc. (NASDAQ:ETON). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ETON forecast page.
Current market data
NASDAQ · ETON
$51.80
Up: +$0.64 · +1.25%
Live quote updated
Keep reading
sec_filing ·
analyst ·
earnings ·
analyst ·